Opko Health Inc Reports Results For The Quarter Ended June 30: Earnings Summary
OPKO Health Inc reports results for the quarter ended June 30 - Earnings Summary
OPKO Health Inc OPK.OQ reported a quarterly adjusted loss of 1 cent per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -19 cents. The mean expectation of six analysts for the quarter was for a loss of 8 cents per share. Wall Street expected results to range from -11 cents to -6 cents per share.
Revenue rose 4.3% to $163.58 million from a year ago; analysts expected $131.23 million.
OPKO Health Inc's reported EPS for the quarter was a loss of 1 cent.
The company reported a quarterly loss of $8.42 million.
OPKO Health Inc shares had fallen by 18.7% this quarter and lost 3.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 14.3% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the healthcare facilities & services peer group is also "buy"
Wall Street's median 12-month price target for OPKO Health Inc is $3.00, about 59.3% above its last closing price of $1.22
This summary was machine generated from LSEG data July 27 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.08 | -0.01 | Beat |
Mar. 31 2026 | -0.07 | -0.07 | Met |
Dec. 31 2025 | -0.07 | -0.04 | Beat |
Sep. 30 2025 | -0.04 | 0.03 | Beat |
Recent news on OPKO Health
See all newsOpko Health, Inc. Expected To Post A Loss Of 7 Cents A Share: Earnings Preview
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
US RESEARCH ROUNDUP-Bank7, Goldman Sachs, Morgan Stanley
Deals of the day-Mergers and acquisitions
US STOCKS ON THE MOVE-Caterpillar, Kimberly-Clark, Bending Spoons